Integrated Pathogen Reduction Technologies for whole blood and blood components for transfusion (R01) Clinical Trial Not Allowed

The Food and Drug Administration (FDA) is seeking to support the development of innovative pathogen reduction technologies for whole blood and blood components to prevent transfusion-transmitted infectious diseases. This opportunity is open to various types of organizations, including higher education institutions, nonprofits, for-profit organizations, and governments. The FDA is looking for applicants to develop technologies that can reduce the risk of transfusion-transmitted infectious diseases. • Eligible applicants include higher education institutions, nonprofits, for-profit organizations, and governments. • The FDA is seeking innovative pathogen reduction technologies for whole blood and blood components. • The goal of this opportunity is to prevent transfusion-transmitted infectious diseases. • The FDA will provide funding for the development of these technologies.